Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first- and second-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study
Abstract
Abstract Background: Helicobacter pylori infection remains a major global health concern, with rising antibiotic resistance posing significant challenges to eradication efforts. The search for novel, effective regimens is particularly important in regions with high resistance rates to standard agents. This study evaluated the efficacy and safety of nitazoxanide-based quadruple therapies incorporating either levofloxacin or moxifloxacin. Methods: In this randomized, multicenter trial, patients with confirmed H. pylori infection—both treatment-naïve and treatment-experienced—received either levofloxacin–nitazoxanide–doxycycline–lansoprazole (LNDL) or moxifloxacin–nitazoxanide–doxycycline–lansoprazole (MNDL) for 14 days. Naïve patients were also assigned to standard triple therapy with amoxicillin, clarithromycin, and lansoprazole (ACL). Eradication was assessed by stool antigen testing. Rates were analyzed using intention-to-treat (ITT) and per-protocol (PP) methods, and adverse events were recorded. Results: Among naïve patients, ITT eradication rates were significantly higher with LNDL (82.3%) than with ACL (59.2%). PP analysis showed eradication rates of 87.2% for LNDL and 81.6% for MNDL, both significantly higher than ACL (60.9%). In treatment-experienced patients, ITT rates were 65.9% for LNDL and 77.3% for MNDL, with PP rates of 72.5% and 82.9%, respectively; differences between LNDL and MNDL were not statistically significant. All regimens were well tolerated, with no…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.